1
|
Yeung CSY, Chiang CL, Wong NSM, Ha SK, Tsang KS, Ho CHM, Wang B, Lee VWY, Chan MKH, Lee FAS. Palliative Liver Radiotherapy (RT) for Symptomatic Hepatocellular Carcinoma (HCC). Sci Rep 2020; 10:1254. [PMID: 31988376 PMCID: PMC6985173 DOI: 10.1038/s41598-020-58108-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 01/10/2020] [Indexed: 12/14/2022] Open
Abstract
This study aims at evaluating the symptom response, response duration, and toxicity of single dose palliative liver radiotherapy (RT) for symptomatic HCC patients. We reviewed unresectable HCC patients treated with palliative RT in our institution. Eligible patients were unsuitable or refractory to trans-arterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT), with an index symptom of pain or abdominal discomfort. The primary outcome was the percentage of patients with clinical improvement of index symptom at 1 month. Secondary outcomes were response duration, toxicities, alpha-feto protein (AFP) response, and radiological response. Fifty-two patients were included in the study. The index symptom was pain in 34 patients (65.4%), and abdominal discomfort (34.6%) in 18 patients. At 1 month, 51.9% of patients had improvement of symptoms. Median time to symptom progression was 89 days (range: 12–392 days). Treatment was well tolerated with only 2 patients (3.8%) developing grade 3 GI toxicities. AFP response, radiological response rate, and disease control rate at 3 months were 48.6%, 15.1%, and 54.5% respectively. Half of the patients had improvement of index symptoms after receiving palliative liver RT with median response duration of 3 months. The treatment was well tolerated with minimal toxicities.
Collapse
Affiliation(s)
- Cynthia S Y Yeung
- Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong (SAR), China
| | - C L Chiang
- Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong (SAR), China. .,Department of Clinical Oncology, University of Hong Kong, Pok Fu Lam, Hong Kong (SAR), China. .,Department of Clinical Oncology, HKU-Shenzhen Hospital, ShenZhen, China.
| | - Natalie S M Wong
- Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong (SAR), China
| | - S K Ha
- Department of Clinical Oncology, University of Hong Kong, Pok Fu Lam, Hong Kong (SAR), China
| | - K S Tsang
- Department of Clinical Oncology, University of Hong Kong, Pok Fu Lam, Hong Kong (SAR), China
| | - Connie H M Ho
- Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong (SAR), China
| | - B Wang
- Department of Clinical Oncology, HKU-Shenzhen Hospital, ShenZhen, China
| | - Venus W Y Lee
- Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong (SAR), China
| | - Mark K H Chan
- Department of Radiation Physics, Imperial College London NHS Healthcare Trust, Charing Cross Hospital, London, UK
| | - Francis A S Lee
- Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong (SAR), China
| |
Collapse
|
2
|
Yasuda T, Tanaka O, Hayashi S, Nakahata Y, Yasuda Y, Omatsu T, Obora A, Kojima T, Matsuo M, Yagi N. Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report. Clin J Gastroenterol 2019; 13:11-16. [PMID: 31321737 DOI: 10.1007/s12328-019-01023-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Accepted: 07/12/2019] [Indexed: 10/26/2022]
Abstract
A 72-year-old man was admitted to the hospital with fatigue. Colonoscopy revealed a 50 × 50 mm rectal tumor with bleeding. Based on close inspection, he was diagnosed with unresectable advanced rectal cancer with multiple liver metastases. Chemotherapy was administered as 10 cycles of bevacizumab + mFOLFOX6 and 7 cycles of bevacizumab + FOLFIRI. Nine months later, he presented with hematochezia and progression of anemia. It was difficult to stop the bleeding via endoscopy. He underwent radiation therapy (39 Gy in 13 fractions), and hemostasis was confirmed. Then, further chemotherapy was performed with 3 cycles of bevacizumab + FOLFIRI and 2 cycles of TAS102. However 14 months after the initial visit, he presented with right hypochondralgia and abdominal fullness due to the progression of multiple liver metastases. Palliative low-dose whole-liver radiation therapy (WLRT) (30 Gy in 10 fractions) was performed. He developed Grade 2 nausea, but his right hypochondralgia reduced, liver dysfunction improved, and he successfully completed radiotherapy. At approximately the same time his anemia progressed, and colonoscopy revealed recurrent bleeding from the tumor. Re-irradiation (15 Gy in 5 fractions) of the rectal tumor was carried out and a blood transfusion was performed for the bleeding. He was discharged after confirmation the anemia had not progressed. Few reports have been published on the use of both palliative re-irradiation to stop bleeding from rectal cancer and palliative low-dose WLRT. Based on our experience with this case, we believe that palliative radiotherapy can be useful in treating patients with a poor prognosis.
Collapse
Affiliation(s)
- Takeshi Yasuda
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan.
| | - Osamu Tanaka
- Department of Radiation Oncology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| | - Sadanari Hayashi
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| | - Yuki Nakahata
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| | - Yuriko Yasuda
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| | - Tatsushi Omatsu
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| | - Akihiro Obora
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| | - Takao Kojima
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| | - Masayuki Matsuo
- Department of Radiology, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan
| | - Nobuaki Yagi
- Department of Gastroenterology, Asahi University Hospital, 3-23, Hashimoto-cho, Gifu, 500-8523, Japan
| |
Collapse
|
3
|
Greco C, Catalano G, Di Grazia A, Orecchia R. Radiotherapy of Liver Malignancies. From Whole Liver Irradiation to Stereotactic Hypofractionated Radiotherapy. TUMORI JOURNAL 2018; 90:73-9. [PMID: 15143976 DOI: 10.1177/030089160409000116] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background Until recently radiotherapy of hepatic malignancies has played a limited role due to the well-known limited radiotolerance of the liver. The aim of this paper is to review the available data on the risk of radiation-induced liver disease (RILD) and to define the modern role of radiotherapy in the management of patients with metastatic or primary liver malignancies. Methods The advent of three-dimensional conformal treatment planning with dose-volume histogram analysis has made the study of partial liver irradiation possible. Limited portions of the liver may withstand high doses of radiation with minimal risk of RILD. Patients with solitary unresectable liver tumors may be treated with high-dose radiotherapy with curative intent. Recently, the feasibility of stereotactically guided treatment techniques with a single fraction or few treatment sessions has been explored in numerous institutions. Results The radiation tolerance of the whole liver found by several investigations is in the order of approximately 30 Gy, which seriously restricts its clinical application. The role of whole liver irradiation therefore appears of limited benefit in the palliation of patients with multiple liver metastases. The use of three-dimensional conformal techniques has made partial liver irradiation possible to doses in the 70–80 Gy range with conventional fractionation. At least two published series have reported improved local control and survival rates with dose escalation with three-dimensional conformal radiotherapy in patients with unresectable liver metastases. Similar outcomes have been recently reported with single dose (or hypofractionated) stereotactic radiotherapy both in metastatic and primary hepatic malignancies with minimal morbidity. Accurate target delineation and treatment reproducibility are the key to the success of this novel treatment approach, and specific treatment planning techniques and patient setup procedures must be developed to implement it. Conclusions Stereotactic high-dose radiotherapy is technically feasible for the treatment of inoperable liver malignancies, with the potential of high local control and low morbidity. Definitive evidence on the clinical advantages of this technique over other more established treatments can only be gathered from well-designed clinical studies.
Collapse
Affiliation(s)
- Carlo Greco
- Division of Radiation Oncology, European Institute of Oncology, Milan, Italy.
| | | | | | | |
Collapse
|
4
|
Qian Y, Kumar KA, Dudley SA, Koong AC, Chang DT. Radiation Therapy for Colorectal Liver Metastases. CURRENT COLORECTAL CANCER REPORTS 2017. [DOI: 10.1007/s11888-017-0368-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
5
|
Choudhary S, Mitra S, Sharma MK, Khullar P, Saxena U. Resurrection of whole liver radiotherapy-A case report. J Egypt Natl Canc Inst 2017; 29:105-108. [PMID: 28258915 DOI: 10.1016/j.jnci.2017.01.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 12/30/2016] [Accepted: 01/04/2017] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION This is a case report of a patient of lymphoma with liver metastasis who had persistent pain and jaundice despite multiple lines of chemotherapy. She underwent palliative liver irradiation. This is an uncommon modality due to fear of radiation induced hepatitis. We reviewed literature available on the use of liver irradiation for palliation and concluded that it can be safely used with good results. A 33-year-old female with Non-Hodgkin's Lymphoma (NHL) presented with obstructive jaundice. She underwent stenting followed by chemotherapy. She was lost to follow up to later present with a progressively increasing right hypochondrial mass, pain and icterus. Ultrasound abdomen revealed massive hepatomegaly with hypodense lesions in both liver lobes and centring the porta with dilatation of biliary radicals. Despite multiple lines of chemotherapy and use of opioids, there was no symptomatic relief in pain, size of mass or any decrease in biochemical parameters. Then she was offered palliative radiation in the form of partial liver irradiation to a dose of 21Gy/7 fractions. She had >50% pain relief after 2 fractions and was off opioids by last fraction. Liver span reduced from 6cm to 1cm below costal margin in mid clavicular line. Radiologically 60% reduction in size of liver lesions was observed. Also, a decreasing trend in biochemical parameters was observed. Use of whole or partial liver irradiation is rare in clinical practice due to fear of radiation induced hepatitis by conventional techniques. Newer techniques of delivering radiation can highly improvise accuracy and permit further dose escalation.
Collapse
Affiliation(s)
| | | | | | - Pooja Khullar
- DNB Radiation Oncology, Batra Hospital, New Delhi, India
| | | |
Collapse
|
6
|
Edyta WR, Jakub L, Jerzy W. Whole Liver Palliative Radiotherapy for Patients with Massive Liver Metastases. Asian Pac J Cancer Prev 2015; 16:6381-4. [DOI: 10.7314/apjcp.2015.16.15.6381] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
7
|
Rusthoven CG, Lauro CF, Kavanagh BD, Schefter TE. Stereotactic body radiation therapy (SBRT) for liver metastases: A clinical review. SEMINARS IN COLON AND RECTAL SURGERY 2014. [DOI: 10.1053/j.scrs.2013.09.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
8
|
Soliman H, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, Brade A, Wong R, Brierley J, Cummings B, Zimmermann C, Dawson LA. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol 2013; 31:3980-6. [PMID: 24062394 DOI: 10.1200/jco.2013.49.9202] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE To evaluate the feasibility and response of liver radiotherapy (RT) in improving symptoms and quality of life in patients with hepatocellular carcinoma (HCC) or liver metastases (LM). PATIENTS AND METHODS Eligible patients had HCC or LM, unsuitable for or refractory to standard therapies, with an index symptom of pain, abdominal discomfort, nausea, or fatigue. The Brief Pain Inventory (BPI), Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep), and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) were completed by patients at baseline and each follow-up. The primary outcome was the percentage of patients with a clinically significant change at 1 month in the BPI subscale of symptom on average in the past 24 hours. Secondary outcomes were improvement in other BPI subscales and at other time points, FACT-Hep and EORTC QLQ-C30 at each follow-up, and toxicity at 1 week. RESULTS Forty-one patients (30 men and 11 women) with HCC (n = 21) or LM (n = 20) were accrued. At 1 month, 48% had an improvement in symptom on average in the past 24 hours. Fifty-two percent of patients had improvement in symptom at its worst, 37% at its least, and 33% now. Improvements in the FACT-G and hepatobiliary subscale were seen in 23% and 29% of patients, respectively, at 1 month. There were also improvements in EORTC QLQ-C30 functional (range, 11% to 21%) and symptom (range, 11% to 50%) domains. One patient developed grade 3 nausea at 1 week. CONCLUSION Improvements in symptoms were observed at 1 month in a substantial proportion of patients. A phase III study of palliative liver RT is planned. [Corrected]
Collapse
Affiliation(s)
- Hany Soliman
- Hany Soliman, Odette Sunnybrook Cancer Centre, University of Toronto; Jolie Ringash, Haiyan Jiang, John Kim, Robert Dinniwell, Anthony Brade, Rebecca Wong, James Brierley, Bernard Cummings, Camilla Zimmermann, and Laura A. Dawson, Princess Margaret Cancer Centre, University of Toronto; and Jolie Ringash and Kawalpreet Singh, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Høyer M, Swaminath A, Bydder S, Lock M, Méndez Romero A, Kavanagh B, Goodman KA, Okunieff P, Dawson LA. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012; 82:1047-57. [PMID: 22284028 DOI: 10.1016/j.ijrobp.2011.07.020] [Citation(s) in RCA: 153] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2011] [Revised: 07/12/2011] [Accepted: 07/25/2011] [Indexed: 12/14/2022]
Abstract
Over the past decade, there has been an increasing use of radiotherapy (RT) for the treatment of liver metastases. Most often, ablative doses are delivered to focal liver metastases with the goal of local control and ultimately improving survival. In contrast, low-dose whole-liver RT may be used for the palliation of symptomatic diffuse metastases. This review examines the available clinical data for both approaches. The review found that RT is effective both for local ablation of focal liver metastases and for palliation of patients with symptomatic liver metastases. However, there is a lack of a high level of evidence from randomized clinical trials.
Collapse
Affiliation(s)
- Morten Høyer
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Liver metastases are a common source of cancer morbidity and mortality and are often the only site of metastases. In the last 2 decades, major technological advancements in radiation treatment planning and delivery have resulted in resurgence in the use of radiation therapy (RT) as a treatment for liver tumors. With the advent of 3-dimensional conformal radiation treatment (CRT), partial liver irradiation became possible. Stereotactic body radiation therapy (SBRT) is a further enhancement, defined as highly focused, stereotactically localized and administered, high-dose RT delivered in a hypofractionated course. There is now more than a decade of experience with CRT and SBRT for the treatment of liver metastases. In selected patients, very high local control rates have been observed, with minimal toxicity. Patients most likely to benefit from RT are those with liver confined disease, focal distribution of metastases, and metastases more than 1.5 cm from luminal gastrointestinal organs. There is growing evidence that strategies using aggressive or ablative local therapies as an adjunct to systemic therapy might achieve improvements in overall outcome as long as they are administered safely.
Collapse
Affiliation(s)
- Tracey E Schefter
- Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
| | | |
Collapse
|
11
|
De Bari B, Guillet M, Mornex F. Radiothérapie en conditions stéréotaxiques des métastases hépatiques. Cancer Radiother 2011; 15:72-6. [DOI: 10.1016/j.canrad.2010.11.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2010] [Accepted: 04/08/2010] [Indexed: 02/08/2023]
|
12
|
De Bari B, Pointreau Y, Rio E, Mirabel X, Mornex F. Dose de tolérance à l’irradiation des tissus sains : le foie. Cancer Radiother 2010; 14:344-9. [DOI: 10.1016/j.canrad.2010.02.013] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2010] [Accepted: 02/19/2010] [Indexed: 01/10/2023]
|
13
|
Hauerstock D, Choi W. Radiotherapeutic Management of Liver Metastases in Colorectal Cancer. SEMINARS IN COLON AND RECTAL SURGERY 2010. [DOI: 10.1053/j.scrs.2010.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
14
|
|
15
|
Bydder S, Spry NA, Christie DRH, Roos D, Burmeister BH, Krawitz H, Davis S, Joseph DJ, Poulsen M, Berry M. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. AUSTRALASIAN RADIOLOGY 2003; 47:284-8. [PMID: 12890250 DOI: 10.1046/j.1440-1673.2003.01177.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The purpose of this study was to prospectively examine the effectiveness and tolerability of a simple radiotherapy technique for the palliation of symptomatic liver metastases. Twenty-eight patients with symptomatic liver metastases were enrolled from seven centres, and received targeted (partial or whole) liver irradiation consisting of 10 Gy in two fractions over 2 days. Symptoms at baseline were hepatic pain (27 patients), abdominal distension (19), night sweats (12), nausea (18) and vomiting (eight). Twenty-two patients (76%) had failed previous treatment with chemotherapy, hormonal therapy and/or high-dose steroids. Symptoms and potential toxicities were prospectively assessed at the time of treatment, then 2, 6 and 10 weeks later. Individual symptom response rates were 53-66% at 2 weeks. Partial or complete global symptomatic responses were noted in 15 patients (54%) overall. The treatment was well tolerated with two patients (7%) experiencing grade 3 toxicity (one vomiting and one diarrhoea); however, four patients reported temporary worsening of pain shortly after treatment. This simple and well-tolerated treatment achieves useful palliation.
Collapse
Affiliation(s)
- S Bydder
- Radiation Oncology, Sir Charles Gairdner Hospital, Western Australia, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
This review discusses the importance of palliation of liver metastases. Although colorectal cancer comprises the majority of patients with metastatic liver disease, a number of other malignancies can be involved. Palliation of metastatic disease to liver has generally not included the use of external-beam radiotherapy because of restricted liver tolerance to radiotherapy. However, more recently, treatment policies have evolved to more generous use of palliative radiotherapy with utilization of tumor boost doses to partial liver volumes. This has resulted in improvement in palliation and a suggestion of improved survival with higher radiotherapy doses, which have been well tolerated by small volumes of liver.
Collapse
Affiliation(s)
- Uzma Malik
- Department of Radiation Medicine, University of Kentucky, Lexington, KY 40536-0293, USA
| | | |
Collapse
|
17
|
Cubillo A, de Castro J, Feliu J, González Barón M. [Current status of the treatment of hepatic metastases of colorectal carcinoma]. Med Clin (Barc) 2000; 114:506-10. [PMID: 10846657 DOI: 10.1016/s0025-7753(00)71346-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A Cubillo
- Servicio de Oncología Médica, Hospital La Paz, Universidad Autónoma de Madrid
| | | | | | | |
Collapse
|
18
|
Cromheecke M, de Jong KP, Hoekstra HJ. Current treatment for colorectal cancer metastatic to the liver. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 1999; 25:451-63. [PMID: 10527592 DOI: 10.1053/ejso.1999.0679] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Surgery is currently the only available treatment option which offers the potential for cure for patients with liver metastases from colorectal cancer. Of those who undergo a potentially curative operation for their primary tumour but subsequently recur, almost 80% will develop evidence of metastatic disease within the liver. Greater experience and improvements in technique in liver surgery, with an increasingly aggressive surgical approach to metastatic colorectal cancer to the liver, has resulted in prolonged disease-free survival with 5-year rates varying from 21% to 48%. In order to increase these numbers further and to treat patients not eligible for surgical therapy, new treatment modalities and strategies have been developed. This review presents an update of the current treatment for colorectal disease metastatic to the liver.
Collapse
Affiliation(s)
- M Cromheecke
- Department of Surgery, Division of Surgical Oncology, Groningen, The Netherlands
| | | | | |
Collapse
|
19
|
Cascinu S, Catalano V, Baldelli AM, Scartozzi M, Battelli N, Graziano F, Cellerino R. Locoregional treatments of unresectable liver metastases from colorectal cancer. Cancer Treat Rev 1998; 24:3-14. [PMID: 9606364 DOI: 10.1016/s0305-7372(98)90067-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- S Cascinu
- Clinica di Oncologia Medica, Scuola di Specializzazione in Oncologia, Università degli Studi di Ancona, Italy
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
Pain is among the most prevalent symptoms experienced by cancer patients. A strategy for the management of cancer pain is now widely accepted, and when well implemented, is usually effective. Unfortunately, many oncologists are ill-prepared for the task of pain assessment and management, and the outcomes achieved in clinical practice are often suboptimal. The various elements in the pain management strategy are described. Patient assessment, the use of primary therapies and systemically administered nonopioid and opioid analgesics are pivotal to the strategy. Practical aspects of opioid pharmacotherapy encompass drug selection and dosing considerations including selection of an appropriate route of administration, dose titration, and the management of side effects. Specific approaches are described for the treatment of patients for whom an acceptable balance between relief and side effects of opioids is not achieved. These comprise noninvasive interventions, including the use of adjuvant analgesics, psychological therapies, and physiatric techniques, and invasive interventions, such as the use of intraspinal opioids, neural blockade, and neuroablative techniques. Finally, the use of sedation in the treatment of patients with pain that is refractory to other interventions is addressed. The skilled application of this strategy can provide adequate relief to the vast majority of patients, most of whom will respond to systemic pharmacotherapy alone. Patients with refractory pain should see specialists in pain management or palliative medicine who can address these difficult problems.
Collapse
Affiliation(s)
- N I Cherny
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021
| | | |
Collapse
|
21
|
Mumper RJ, Jay M. Poly(L-lactic acid) microspheres containing neutron-activatable holmium-165: a study of the physical characteristics of microspheres before and after irradiation in a nuclear reactor. Pharm Res 1992; 9:149-54. [PMID: 1589401 DOI: 10.1023/a:1018908600711] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The solvent evaporation technique was employed to prepare poly(L-lactic acid) (PLA) microspheres with 165Ho acetylacetonate (Ho-AcAc). Particle size, percentage Ho-165, percent residual solvent, and retentive ability of the spheres were found to be strongly affected by preparatory conditions. Differential scanning calorimetry (DSC) thermograms suggested that the Ho-AcAc existed in the PLA matrix as a molecular dispersion. High neutron flux irradiations of the PLA spheres in a nuclear reactor produced Ho-166, a therapeutic radionuclide that emits high-energy negatrons (Emax = 1.84 MeV; half-life = 26.9 hr). The gamma radiation dose (53-75 Mrad) from the core of the reactor provided an overkill of all bioburdens in the PLA spheres. Gel permeation chromatography (GPC) analysis showed that these irradiations caused a reduction in PLA molecular weight. Infrared spectra, 13C NMR spectra, 1H NMR spectra, and DSC thermograms further confirmed the presence of lower molecular weight PLA but proved the overall maintenance of PLA structure.
Collapse
Affiliation(s)
- R J Mumper
- Division of Medicinal Chemistry and Pharmaceutics, College of Pharmacy, University of Kentucky, Lexington 40536-0082
| | | |
Collapse
|
22
|
Adjuvant therapy with hepatic irradiation plus fluorouracil in colon carcinoma. The Gastrointestinal Tumor Study Group. Int J Radiat Oncol Biol Phys 1991; 21:1151-6. [PMID: 1938512 DOI: 10.1016/0360-3016(91)90270-e] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In an attempt to reduce disease recurrence after curative resection of transmural or node positive colon cancer, the Gastrointestinal Tumor Study Group performed a randomized trial of observation versus 5-FU plus 2100 cGy to the liver. A total of 300 eligible trial participants form the basis of this report. Significant toxicity after the combination caused major dose reduction from the original course of 500 mg/m2 to 350 mg/m2. No therapeutic benefits were noted in either survival or recurrence endpoints; the liver recurrence rate was not decreased by the therapy. Analysis of patients with transmural colonic involvement and negative nodes, one to four positive, and greater than four positive nodes indicates that not all patients are alike with respect to disease outcome or overall survival, and that node number is an important determinant of patient selection for adjuvant trials.
Collapse
|
23
|
Nag S. Radiotherapy and brachytherapy for recurrent colorectal cancer. SEMINARS IN SURGICAL ONCOLOGY 1991; 7:177-80. [PMID: 2068453 DOI: 10.1002/ssu.2980070312] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Radical surgical excision of locoregional recurrence of colorectal carcinoma usually produces the best survival and should be attempted whenever possible. However, recurrences are often unresectable; hence palliative local therapy may be indicated. There are several options for the radiation therapy of local, unresectable, recurrent, or metastatic colorectal cancer. Whole pelvis irradiation of 4,000-5,000 cGy followed by a coned-down boost of 1,000-1,500 cGy generally provides good symptomatic palliation in 80-90% of patients, but long-term control or cure is rarely achieved. External beam irradiation of 2,000-3,000 cGy to the whole liver with or without concurrent chemotherapy may be used for palliation of metastatic disease to the liver. A combination of intraoperative radiation therapy applied directly to the tumor bed and external beam irradiation may improve local control and survival rates. Multiple options are available for the intraoperative use of brachytherapy which can deliver high radiation doses to the residual tumor, or tumor bed, sparing normal tissue.
Collapse
Affiliation(s)
- S Nag
- Section of Brachytherapy, Ohio State University, Columbus
| |
Collapse
|
24
|
Pillai KM, McKeever PE, Knutsen CA, Terrio PA, Prieskorn DM, Ensminger WD. Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumor. SELECTIVE CANCER THERAPEUTICS 1991; 7:39-48. [PMID: 1754728 DOI: 10.1089/sct.1991.7.39] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Microspheres conjugated to radioisotopes and chemotherapeutic agents are playing an important investigative and clinical role in the management of metastatic neoplasms. The purpose of our investigation was to histologically assess the basis for regional intra-arterial microsphere therapy, by comparing the spatial distribution of microspheres in the tumor and liver of experimental models of hepatic metastases. Three New Zealand white rabbits with hepatic VX2 tumor implants were arterially injected with hepatic doses of either 15 or 30 million blue-dyed, polystyrene microspheres (27 microns-diameter). Microscopic examination of random liver and tumor samples revealed that 6-12 times as many microspheres were embolized within tumor than in normal liver (p less than 0.002). The majority of microspheres aggregated into clusters of various size within liver and tumor vasculature, though analysis of cluster sizes illustrated an exponentially skewed distribution toward isolated microspheres. Approximately eight times as many clusters were observed in tumor than in liver (p less than 0.008). Finally, a morphometric analysis was used to quantitate the minimal distances separating microsphere clusters, the intercluster distance (ICD). Analysis of over three thousand intercluster measurements revealed a median ICD approximately five times lower in tumor than in liver (p less than 1 x 10(-8)). This microquantitative analysis provides a fundamental description of how regional intra-arterial microsphere therapy allows the targeted delivery of microspheres to neoplastic tissue, to potentially improve the therapeutic index in the treatment of hepatic metastases.
Collapse
Affiliation(s)
- K M Pillai
- Department of Pathology, University of Michigan Medical School, Ann Arbor 48109
| | | | | | | | | | | |
Collapse
|
25
|
JIRTLE RANDYL, ANSCHER MITCHELLS, ALATI TERESA. Radiation Sensitivity of the Liver. ADVANCES IN RADIATION BIOLOGY 1990. [DOI: 10.1016/b978-0-12-035414-6.50013-4] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
26
|
Wiley AL, Wirtanen GW, Stephenson JA, Ramirez G, Demets D, Lee JW. Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study. Cancer 1989; 64:1783-9. [PMID: 2790692 DOI: 10.1002/1097-0142(19891101)64:9<1783::aid-cncr2820640904>3.0.co;2-q] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The effect of hepatic irradiation (RT) after intraarterial 5-fluorouracil (5-FU) was evaluated in 37 randomized patients with colorectal adenocarcinoma hepatic metastases. Patients underwent percutaneous transbrachial artery catheterization of the hepatic artery followed by 21-day continuous 5-FU infusion (CT). Hepatic irradiation of 25.5 Gy was delivered to 19 patients 14 days after completion of infusion (CT + RT). All patients received subsequent weekly maintenance 5-FU. A 37% (seven of 19) response rate was observed in CT + RT, and a 50% response rate (nine of 18) in CT: median survival was 6 months for CT + RT, and 8 months for CT, (P = 0.106). Improved survival was observed in two subsets of patients. Tumor vascularity was graded angiographically from 0 to 4+; those patients with highest vascularity (4+) had a 20-month median survival (P = 0.0009). Patients with Grade 1, well-differentiated, histologic type had a median survival of 20 months (P = 0.0001). Four patients with both 4+ vascularity and Grade 1 histologic type had 27.5 months' median survival (P = 0.0019). Age, performance status, elevated liver function tests, previous systemic therapy, and time interval between diagnosis and entry on this study did not impact on survival (P greater than 0.05), nor did these variables eliminate the significance of vascularity and grade (P less than 0.05). Survival after intraarterial 5-FU infusion was not improved by this regimen of sequential external irradiation. Regional therapy may benefit those patients with 4+ vascular tumors and/or well-differentiated tumor grade. Future trials are needed to explore the interaction of halogenated pyrimidines with irradiation and determine whether these prognostic factors can aid in patient selection for regional therapy of hepatic metastases.
Collapse
Affiliation(s)
- A L Wiley
- Department of Human Oncology, University of Wisconsin Medical Center, Madison
| | | | | | | | | | | |
Collapse
|
27
|
Abstract
Hepatic metastases represent a common site of dissemination for a number of primary malignancies related in part to the dual blood supply, large blood flow, and receptive environment of the hepatic parenchyma. Although this review focuses on regional therapy, we have included sections on systemic therapy to better interpret the results with intrahepatic therapy. We will also discuss the efficiency of hepatic arterial ligation, embolization, and radiotherapy of hepatic metastases. Primary gastrointestinal neoplasms are particularly prone to produce hepatic metastases. Because colorectal carcinoma metastasizes to the liver in up to 70% of patients with advanced disease, the treatment of hepatic metastases is a relevant topic. We will discuss the systemic and regional therapy of colorectal, gastric, and gallbladder cancers. Breast carcinoma and malignant melanoma frequently metastasize to the liver, and we have described systemic and regional treatments of these diseases. Because sarcomas are often treated by regional therapy, we have included a section on the treatment of hepatic sarcomas. Neuroendocrine tumors (carcinoid and islet cell), although often slow growing, frequently metastasize to the liver and then cause symptomatic problems. Much of the work done with embolization and hepatic ligation in the treatment of hepatic metastases has been performed in neuroendocrine tumors, and these studies, as well as the systemic and regional chemotherapy of hepatic metastases, will be described. The last section concerns the treatment of hepatocellular carcinoma. We have outlined the staging systems used. We then detail the results of systemic and intrahepatic therapy, embolization, and hepatic ligation in the treatment of hepatocellular carcinoma. Because hepatic metastases are a frequent problem, many patients are available for clinical investigation. It is hoped that newer strategies for the treatment of liver metastases will lead to higher response rates and perhaps control of local disease. These therapeutic approaches may also give us leads to the treatment of systemic disease.
Collapse
Affiliation(s)
- N Kemeny
- Gastrointestinal Tumor Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | | |
Collapse
|
28
|
Glimelius B, Påhlman L. Cytostatic drug therapy in disseminated colorectal cancer. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. SUPPLEMENT 1988; 149:181-9. [PMID: 2974175 DOI: 10.3109/00365528809096979] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
5-FU is the best available single drug in advanced colorectal disease. After systemic administration approximately 15% of the patients achieve a short-lived objective remission. Survival is not prolonged by therapy. Several chemotherapy combinations have in preliminary phase II studies given higher response rates (30-50%), but when evaluated in controlled studies, no advantage over single-drug 5-FU has been verified. At present, two combinations, MOF-S and sequential MTX/5-FU/Leucovorin seem promising, but more experience is needed before general acceptance. In cases of liver dissemination, regional hepatic infusion therapy causes objective tumour regression more often than systemic therapy. However, median survival is most likely the same for both treatment modalities, and since hepatic artery infusion is the most expensive therapeutic modality, routine use of hepatic artery infusion is discouraged. Outside clinical trials, systemic or regional chemotherapy is hardly indicated in advanced colorectal disease apart from certain selected symptomatic patients.
Collapse
Affiliation(s)
- B Glimelius
- Dept. of Oncology and Surgery, University of Uppsala, Sweden
| | | |
Collapse
|
29
|
Leibel SA, Pajak TF, Massullo V, Order SE, Komaki RU, Chang CH, Wasserman TH, Phillips TL, Lipshutz J, Durbin LM. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys 1987; 13:1057-64. [PMID: 3597149 DOI: 10.1016/0360-3016(87)90045-9] [Citation(s) in RCA: 65] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Between May 1980 and July 1983, the RTOG conducted a randomized prospective study comparing external radiation therapy and misonidazole to radiation therapy alone for patients with hepatic metastases. Two hundred fourteen patients were accessioned to this study of whom 187 were evaluable. Radiation therapy was delivered to the whole liver to a dose of 21.0 Gy in 7 fractions. Misonidazole was administered orally, 1.5 gm/m2 daily 4-6 hr before each treatment. Patients in the two treatment groups were evenly distributed with respect to stratification variables including primary site, extent of metastatic disease, and Karnofsky Performance Score (KPS). End points examined included amelioration of hepatic pain, improvement of KPS and alkaline phosphatase, decrease in liver and tumor size, and survival. The addition of misonidazole did not significantly improve the therapeutic response to radiation therapy in any of the parameters studied. Hepatic irradiation was effective in relieving abdominal pain with 80% of the symptomatic patients achieving improvement following therapy. Pain was completely relieved in 54% of these patients. Patients with liver metastases from colon carcinoma improved more frequently than those with metastases from other primary tumor sites (p = 0.02). Relief of pain occurred more frequently in patients treated with radiation therapy and misonidazole (87%) compared with radiation therapy alone (74%) (p = 0.08). Palliation of pain was prompt, occurring within a median of 1.7 weeks from the initiation of treatment, and 94% of patients who improved did so within 6 weeks of treatment. The median duration of response was 13.0 weeks in the symptomatic patients; 52% of those surviving 3 months remained improved. KPS improved in 28% of patients. Serial CT scans revealed a partial response in 7% and a marginal response in 13% of patients. One patient had a complete response to treatment. The median survival of patients treated in this series was 4.2 months with no difference between the two treatment groups. Patients with metastases from colon carcinoma and an initial KPS of 80 or more (48% of the patient population) had a median survival of 5.8 months with radiation therapy alone compared with 6.6 months with radiation therapy and misonidazole (p = 0.36). There was no significant treatment related morbidity. Radiation therapy remains an excellent palliative tool for the management of patients with symptomatic hepatic metastases. Further research must continue to identify new methods of selectivity enhancing the tumor response to radiation therapy.
Collapse
|
30
|
zum Winkel K, Wieland C, Weischedel U. Therapeutic strategies in primary and metastatic liver cancer: indication and results of external radiation therapy. Recent Results Cancer Res 1986; 100:289-97. [PMID: 3526469 DOI: 10.1007/978-3-642-82635-1_36] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
31
|
Chamberlain MN, Gray BN, Heggie JC, Chmiel RL, Bennett RC. Hepatic metastases--a physiological approach to treatment. Br J Surg 1983; 70:596-8. [PMID: 6626920 DOI: 10.1002/bjs.1800701009] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Hepatic metastases derived from primary malignancy of the gastrointestinal tract have a grave prognosis, with median survival rates varying from 3 to 11 months. Surgery for isolated metastases and intrahepatic artery chemotherapy are the most effective treatment options currently available. We have explored the potential use of radioactive microspheres delivered into the liver by the hepatic artery as a form of internally irradiating metastatic liver cancer. Microspheres containing radioactive Yttrium injected into the hepatic artery concentrate in the metastases rather than normal liver parenchyma, due to the fact that the blood supply of metastases is derived preferentially from the hepatic artery. Using a rabbit tumour model, radioactive microspheres delivered into the hepatic artery have been shown to lodge preferentially in tumour tissue. The therapeutic application of this phenomenon is that metastases may receive many times the radiation dose delivered to normal liver parenchyma when radioactive microspheres are delivered into the hepatic artery. This would mean that a mean dose of 30 Gy delivered to normal liver tissue would result in greater than 150 Gy being delivered to tumour tissue. Current results in experiments suggest that this form of treatment may have considerable potential for prolonging survival of patients with hepatic metastases.
Collapse
|
32
|
Sonoda T, Reynolds RD, Galey WT. The computerized tomographic appearance of patchy liver congestion due to irradiation. COMPUTERIZED RADIOLOGY : OFFICIAL JOURNAL OF THE COMPUTERIZED TOMOGRAPHY SOCIETY 1983; 7:135-40. [PMID: 6851501 DOI: 10.1016/0730-4862(83)90188-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
33
|
Stribley KV, Gray BN, Chmiel RL, Heggie JC, Bennett RC. Internal radiotherapy for hepatic metastases I: The homogeneity of hepatic arterial blood flow. J Surg Res 1983; 34:17-24. [PMID: 6823100 DOI: 10.1016/0022-4804(83)90017-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Internal radiotherapy, in the form of arterially infused yttrium-90-labeled microspheres, theoretically appears encouraging as a method of treatment for hepatic metastases. Previous investigators have assumed a homogeneous distribution of these microspheres and given dosages of isotope based solely on an estimated liver mass. The purpose of this study has been to establish the homogeneity of isotope distribution in liver substance when 15 micrometers microspheres are arterially injected. This has been done in three mammalian species, with the results expressed as a mean percentage coefficient of variation of 28 +/- 5%. Also demonstrated is the fact that 15 micrometers particles, while not penetrating to the venous circulation, achieve a more homogeneous spread throughout the liver than larger particles. It has been demonstrated that to achieve this maximum homogeneity distribution, 4000 beads/g of liver tissue are required. This equates in the therapeutic situation to a maximum activity of 4 Ci/g of infused microspheres. These results are considered significant in that they indicate criteria necessary to achieve the maximum homogeneity of therapeutic agent within liver substance when it is administered by this method, and will allow confidence limits to be attached to direct in vivo measurement of hepatic irradiation.
Collapse
|
34
|
Abstract
Metastatic cancer of the liver has a dominant influence upon survival despite the presence of metastasis in other sites. For patients with untreated liver metastases, the median survival after diagnosis is 75 days, and only 7% survived 1 year. Prognosis of hepatic metastasis is related to the extent of liver involvement, and various staging systems have been proposed (Table I.1). Hepatic metastases are quite resistant to conventional systemic chemotherapy. Surgical resection is the treatment of choice whenever possible, but the resectability rate is rather low and the surgical mortality relatively high. Patients with solitary metastasis and those with primary in the colon, especially females, have had the best results. Regional chemotherapy to the liver has the advantages of achieving higher local concentrations of drug, prolonging the contact of drug and tumor cells, and reducing systemic toxicity. Infusion catheter can be placed either percutaneously or directly at the time of celiotomy. Many reports show that hepatic IA infusion of chemotherapeutic agents (5FU or FUDR) can give favorable response in 55%-80% of the cases and can prolong survival in comparison with untreated patients or patients receiving systemic chemotherapy (Tables I.2 and I.3). Some investigators have added one or more other agents to improve the therapeutic results. For instance, patients who were refractory to 5FU or MMC given as a single IV drug responded to the combination infusion therapy. Evidence from animal and human studies have demonstrated that both primary and metastatic tumors in the liver receive their blood supply almost exclusively from the hepatic arterial system, whereas normal liver tissue has a double supply: the hepatic artery and the portal vein. Thus, deliberate ligation of the hepatic artery has been used as a treatment of metastatic tumors of the liver. From 1966 to 1981, some 518 patients were reported to have undergone this operation as compared to 2327 patients treated with hepatic IA infusion chemotherapy (Table I.4). Although selective necrosis of tumor nodules has been demonstrated after HAL, there is always a shell of viable malignant cells left at the periphery. Thus, several series have administered chemotherapeutic agents either to the distal hepatic artery or to branches of the portal vein to prevent tumor regrowth. Currently there is no definite evidence that HAL with added infusion chemotherapy to the liver gives better response and/or survival results than infusion chemotherapy via the hepatic artery only and/or via the portal vein branches. The availability of a totally implantable infusion pump represents a remarkable advance in long-term i
Collapse
|
35
|
Volberding PA, Friedman MA, Resser KJ, Phillips TL. Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate. Cancer Chemother Pharmacol 1982; 9:17-21. [PMID: 7139849 DOI: 10.1007/bf00296755] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Twenty-seven patients with liver metastasis from colorectal cancer were treated with intrahepatic arterial chemotherapy and external radiotherapy consisting of 5-fluorouracil (5-FU) (10 mg/kg/day for 8 days), adriamycin (5 mg/m2/day for 7 days) and methotrexate (MTX) (240 mg/m2/X1), combined with 2,100 rads of whole liver irradiation. Twenty of these patients (74%) had previously received systemic chemotherapy. Of the 21 patients who could be fully evaluated, seven (33%) had an objective partial response and another 10 (48%) had stable disease following treatment. The median duration of survival for all patients after initiation of treatment was 6.5 months. Those patients responding to therapy survived longer (12.7 months) than those who had stable disease (5.5 months) or disease progression (2.5 months). The response rate was not affected by previous chemotherapy. Additionally, of the 14 patients with symptoms related to the disease, nine (64%) experienced substantial relief of these symptoms. Toxicity with the therapy used in this study was generally moderate. The median nadiR WBC was 3,500 cells/mm3; the median nadir platelet count, 121,000 cells/mm3. There was, however, one treatment-associated fatality from sepsis in a patient whose WBC was 900 cells/mm3.
Collapse
|
36
|
Ariel IM, Padula G. Treatment of asymptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 1982; 20:151-6. [PMID: 7201051 DOI: 10.1002/jso.2930200304] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Forty patients with asymptomatic metastatic cancer to the liver discovered at the time of laparotomy were treated by combined intrahepatic arterial chemotherapy and internal irradiation in the form of 90Yttrium microspheres. One group of 25 patients were treated by a catheter inserted at the time of operation and received 100 mCi; of 90Yttrium microspheres and 5-fluorouracil on a continuing basis. They survived an average of 26 mo (varying from 9 to 60 mo). The second series of 15 patients referred after surgery were treated by the percutaneous insertion of the catheter into the hepatic artery and received a bolus of combined chemotherapy consisting of PlatinolTM, Methotrexate, and 5-fluorouracil. They survived an average of 31 mo, which varied from 12 to 60 mo. The dose of 100 mCi of 90Yttrium was well tolerated by the liver. Prospective studies are in progress, limiting the treatment to the internal irradiation to determine its precise role in the overall treatment of metastatic cancer to the liver.
Collapse
|
37
|
Lokich J, Kinsella T, Perri J, Malcolm A, Clouse M. Concomitant hepatic radiation and intraarterial fluorinated pyrimidine therapy: correlation of liver scan, liver function tests, and plasma CEA with tumor response. Cancer 1981; 48:2569-74. [PMID: 7306916 DOI: 10.1002/1097-0142(19811215)48:12<2569::aid-cncr2820481205>3.0.co;2-#] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Sixteen patients with metastatic disease to the liver (12 colorectal and four unknown primary tumors) were treated in a pilot study of hepatic irradiation (2500-3000 rads in 10-12 fractions) delivered concomitantly with continuous short-term intraarterial infusion of 5-fluorouracil (1 g/d) or FUDR (0.5 mg/kg/d) via a percutaneously placed hepatic artery catheter. Abnormal liver function tests, including SGOT, LDH, and alkaline phosphatase, decreased in all patients by day 7-10 of treatment, and other metabolic factors, including serum cholesterol, calcium, albumin, phosphorous, and uric acid, also decreased, often to subnormal levels by termination of treatment (day 15-20). These chemical alterations did not correlate with tumor response in that the identical pattern was observed in responders (ten patients) as well as nonresponders (six patients). Objective determinants of response were assessed by serial monitoring of the plasma carcinoembryonic antigen (CEA) and liver scan. In 14 patients with elevated CEA levels, tumor response (nine patients), nonresponse (four patients), and relapse (five patients) was predicted and confirmed by sequential monitoring of CEA. In one patient, a paradoxical decrease in plasma CEA was associated with progressive disease. The liver scan identified all responding patients but was difficult to quantitate and was delayed for months following subjective clinical response and changes in plasma CEA levels.
Collapse
|
38
|
Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys 1981; 7:587-91. [PMID: 6168623 DOI: 10.1016/0360-3016(81)90370-9] [Citation(s) in RCA: 150] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
39
|
|
40
|
Gray BN. Colorectal cancer: the modern treatment of disseminated disease - a review. THE AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY 1980; 50:647-58. [PMID: 7008762 DOI: 10.1111/j.1445-2197.1980.tb04218.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Most patients who develop cancer of the large bowel will eventually develop recurrence and will therefore be considered for treatment of that recurrence. There exists very great confusion as to the efficacy of the various treatment options available. This review has attempted to evaluate critically the claim for therapeutic efficacy of the various treatment options, with particular regard to patients with liver metastases from primary tumours of the large bowel. A case can be made out for surgical removal of recurrent or disseminated colorectal cancer, but there is no evidence that any form of treatment other than total surgical excision will result in prolonged patient survival. All forms of treatment can be effective in palliating symptomatic patients. Therefore, with the exception of total surgical excision of recurrent tumour, treatment should be reserved for those patients with symptoms, and the choice of treatment offered should be weighed against possible side-effects.
Collapse
|
41
|
Friedman M, Cassidy M, Levine M, Phillips T, Spivack S, Resser KJ. Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study. Cancer 1979; 44:906-13. [PMID: 113078 DOI: 10.1002/1097-0142(197909)44:3<906::aid-cncr2820440318>3.0.co;2-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Twenty-two patients with adenocarcinoma metastatic to the liver were treated with rapid fractionation whole-liver irradiation (1350-2100 rads in 300-rad fractions) with simultaneous intrahepatic 5-fluorouracil (10-15 mg/kg/day) and intrahepatic Adriamycin 2.5-10 mg/m2/day) as part of a Phase I-II study. Of the 21 patients who completed therapy, 19 had colorectal carcinoma and 2 had metastatic adenocarcinoma of unknown origin. Objective response was judged by measurement of liver size, evaluation of liver function tests, and by liver scan or CAT scan of the liver. Ten of the 21 evaluable patients responded, yielding an overall response rate of 47.6%. The response rate in patients with colorectal carcinoma was 55% (10/19). At this time, median duration of response is 14+ weeks and median survival from onset of therapy is 15+ weeks. Hematologic and gastrointestinal toxicity were tolerable. No hepatic toxicity was documented. This combined modality therapy was found to be a safe effective method for the palliation of liver metastasis.
Collapse
|
42
|
Abstract
Two groups of patients were observed for evidence of acute radiation hepatitis during "high dose" radiation to the liver. The first group of 18 patients with metastatic liver disease received an average of 4,050 rad to the whole liver. Half received anticoagulation with warfarin. One patient on anticoagulation developed evidence of acute radiation hepatitis while 2 patients did so without anticoagulation. Eleven patients with Hodgkin's disease received 4,000 rad to the left lobe of the liver during extended field radiation. Four of these 11 patients were anticoagulated to therapeutic range. Only one of the fully anticoagulated patients showed changes on liver scan consistent with radiation hepatitis whereas three did so without anticoagulation. No serious sequelae from anticoagulation occurred in either group. These preliminary data suggest that anticoagulation may be safely administered with high dose hepatic radiation and that further trials with anticoagulation are warranted.
Collapse
|
43
|
Abstract
Forty-eight patients with liver metastases were treated at Rhode ISland Hospital in a nonrandomized sequential manner between January 1972 and June 1977. Eight received 5 FUDR hepatic artery infusion, 14 hepatic irradiation, and 25 were planned for combined intra-arterial chemotherapy plus total hepatic irradiation. Those patients who successfully completed induction treatments had a median survival in the radiation only group of 140 days, in the intra-arterial chemotherapy group 270 days, and in the combined group 376 days. Hepatic radiation when combined with chemotherapy was well tolerated. Primary tumor site, disease duration, and degree of abnormality of liver function had no relationship to the response to treatment. The pretreatment performance level of the patient as determined by the Karnofsky Performance Index gave the best indication for potential response to combined therapy. Based on the results of this treatment and the reports of other series, it appears that the combination of intra-arterial 5 FUDR plus hepatic irradiation may offer prolonged and worthwhile palliation to appropriately chosen patients.
Collapse
|
44
|
Abstract
Between 1971 and 1975, 55 patients underwent palliative radiation therapy for symptomatic hepatic metastasis. Most patients received 2400 rad in 300 rad fractions to the entire liver. There were 31 patients who received concomitant chemotherapy, and 14 who were prior chemotherapy failures. Ninety percent of the patients with symptomatic pain and liver enlargement and significant palliation of their symptoms. The median survival of the entire group was 4.5 months, while those patients experiencing an excellent response (21) had a median survival of 9 months. The median survival of patients having an excellent response to radiation is comparable to that of patients having regional arterial chemotherapy while incuring fewer complications. The overall complication rate of those patients completing therapy (50) was 12%.
Collapse
|